Cargando…

A look-back at convalescent plasma to treat COVID-19

Detalles Bibliográficos
Autores principales:	Garraud, Olivier, Lacombe, Karine, Tiberghien, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802586/ https://www.ncbi.nlm.nih.gov/pubmed/33478889 http://dx.doi.org/10.1016/j.transci.2021.103063

Ejemplares similares

Convalescent plasma to treat COVID-19: Following the Argentinian lead
por: Tiberghien, Pierre, et al.
Publicado: (2021)

Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps
por: Garraud, O., et al.
Publicado: (2021)

L-66 Le plasma convalescent COVID-19 pour le traitement de la COVID-19
por: Tiberghien, Pierre, et al.
Publicado: (2022)

Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
por: Garraud, Olivier
Publicado: (2020)

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
por: Kroemer, Marie, et al.
Publicado: (2022)

Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
por: Lacombe, Karine, et al.
Publicado: (2023)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
por: Hueso, Thomas, et al.
Publicado: (2020)

Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
por: Garraud, Olivier, et al.
Publicado: (2023)

Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis
por: Hueso, Thomas, et al.
Publicado: (2022)

What has changed after the COVID-19 pandemic in the publication process? A look-back to “Transfusion clinique et biologique”
por: Garraud, O.
Publicado: (2021)

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
por: London, Jonathan, et al.
Publicado: (2020)

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Convalescent plasma to treat COVID-19: clinical experience and efficacy
por: Pei, Shiyao, et al.
Publicado: (2021)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection
por: Murphy, Michael, et al.
Publicado: (2020)

Predictors of mortality in COVID-19 patients treated with convalescent plasma therapy
por: Rahimi-Levene, Naomi, et al.
Publicado: (2022)

Convalescent plasma from people vaccinated after COVID-19 infection
por: Jabal, Kamal Abu, et al.
Publicado: (2021)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Convalescent plasma for patients with COVID-19
por: Zeng, Furong, et al.
Publicado: (2020)

Serosurveys and convalescent plasma in COVID-19
por: Pérez-Cameo, Cristina, et al.
Publicado: (2020)

COVID-19 convalescent plasma transfusion
por: Langhi, Dante Mário, et al.
Publicado: (2020)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Evaluation of SARS‐CoV‐2 antibody titers and potency for convalescent plasma donation: a brief commentary
por: Wouters, Elise, et al.
Publicado: (2020)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021)

Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021)

Functional Antibodies in COVID-19 Convalescent Plasma
por: Herman, Jonathan D., et al.
Publicado: (2021)

Challenges of Convalescent Plasma Therapy on COVID-19
por: Zhao, Qian, et al.
Publicado: (2020)

Looking back on forward-looking COVID models
por: Chong, Paul, et al.
Publicado: (2022)

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
por: Kunze, Katie L., et al.
Publicado: (2021)

A patient affected by critical COVID-19 pneumonia, successfully treated with convalescent plasma
por: Einollahi, Behzad, et al.
Publicado: (2020)

Convalescent Plasma for the Treatment of Severe COVID-19
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19, Hypercoagulability, and Cautiousness with Convalescent Plasma
por: Sanfilippo, Filippo, et al.
Publicado: (2021)

Convalescent plasma in patients hospitalised with COVID-19
por: Liu, Sean T H, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ls9ujc33sa74sqq6vs67d9su2